Immunotherapy plus chemotherapy before surgery for colon cancer
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial studies giving chemotherapy plus immune therapy before surgery for certain colon cancers that do not have mismatch repair defects (MSS/pMMR). The goal is to shrink and control the tumor and improve outcomes compared with standard approaches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have colon adenocarcinoma that is MSS (or pMMR).
- Your tumor is located more than 12 cm from the anus and cannot be felt during a rectal exam.
- Your cancer stage is T1–T4 with lymph node involvement (N+) or T3/4, with no distant spread or multiple primary cancers.
- You have not had any prior anti-cancer treatment and you can safely receive chemotherapy.
- You can have contrast CT scans and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests a combination of chemo, a medicine that blocks blood vessel growth, and an immune checkpoint drug given before rectal cancer surgery. It’s for people with locally advanced rectal cancer without distant spread, to try to shrink the tumor and improve surgical results.
This trial tests a combination of chemotherapy, an immunotherapy drug (anti-PD-1 antibody), and sitagliptin before surgery for colorectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor and improve outcomes.
This Phase 2 study tests penpulimab (an immunotherapy medicine) given with CAPEOX chemotherapy before surgery for rectal cancer that is “MSS” (not the mismatch-repair type). It aims to shrink the tumor and improve outcomes by treating before the operation.
This trial tests immunotherapy plus chemotherapy given before surgery for colon cancer that hasn’t spread. It aims to shrink or control the tumor and improve outcomes in people whose tumor has certain immune/biologic features.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with high-risk MSS colon cancer. It is for patients who have not yet received treatment.
Hear when a new Colon Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.